BioAge Labs (NASDAQ:BIOA) Trading Up 8.7% – Here’s Why

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) were up 8.7% during mid-day trading on Friday . The stock traded as high as $17.76 and last traded at $17.8730. Approximately 82,522 shares traded hands during trading, a decline of 86% from the average daily volume of 586,678 shares. The stock had previously closed at $16.45.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on BIOA shares. BTIG Research started coverage on BioAge Labs in a report on Wednesday, May 13th. They set a “buy” rating and a $40.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Citigroup raised their price target on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Finally, Oppenheimer assumed coverage on BioAge Labs in a research report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price target for the company. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.50.

BioAge Labs Price Performance

The firm has a market cap of $792.99 million, a PE ratio of -7.43 and a beta of 0.94. The stock has a 50-day moving average price of $17.18 and a 200 day moving average price of $17.02.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. The business had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. As a group, equities research analysts anticipate that BioAge Labs, Inc. will post -2.68 earnings per share for the current year.

Institutional Investors Weigh In On BioAge Labs

A number of institutional investors have recently added to or reduced their stakes in the company. CWM LLC grew its position in BioAge Labs by 39.9% during the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after acquiring an additional 1,053 shares during the period. Price T Rowe Associates Inc. MD grew its position in BioAge Labs by 24.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,808 shares of the company’s stock valued at $196,000 after acquiring an additional 2,917 shares during the period. Barclays PLC grew its position in BioAge Labs by 9.3% during the fourth quarter. Barclays PLC now owns 37,780 shares of the company’s stock valued at $500,000 after acquiring an additional 3,222 shares during the period. Bank of America Corp DE grew its position in BioAge Labs by 46.3% during the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after acquiring an additional 3,517 shares during the period. Finally, Russell Investments Group Ltd. purchased a new stake in BioAge Labs during the third quarter valued at about $27,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.